Division of Chiesi Farmaceutici SPA
Latest From Zymenex AS
Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.
European Notebook: EC Pharma Policy Reorganized; Early Access To Medicines Scheme Starts; U.K. Changing Merger Regs
Changes in responsibilities in new European Commission were welcomed by industry but not by health activists; and a brain cancer vaccine being developed by American biotech is selected to pioneer new early access scheme for innovative drugs being set up in the U.K.
GSK and CCNC, a non-profit network of health care providers, are developing a medication management analytics system that could get them into the health care IT business. For GSK, the main goal is to learn about changing dynamics of health care delivery systems, in a venture that is entirely independent of the company’s core drug business.
A busy summer of biotech acquisitions, including the pricey buyouts of Onyx by Amgen and Elan by Perrigo, has lifted the number of U.S. public biotech acquisitions so far in 2013 – and increased the average value of those deals. In other deal news, Endo plans to acquire Boca Pharmacal, Medimmune will buy out Amplimmune, and Eli Lilly signed a diabetes research deal with Zealand Pharma.
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- HemeBiotech AS
- Western Europe
- Parent & Subsidiaries
- Chiesi Farmaceutici SPA
- Senior Management
Jens Fogh, Pres. & CEO
Claes Andersson, PhD, Rsch. Dir.
- Contact Info
Phone: (45) 48250054
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.